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Summary
Here,we retrospectively review imaging of 68 consecutive unselected patientswith BRAFV600-mutantmetastatic
melanoma for organ-specific response and progression on vemurafenib. Complete or partial responses were less
often seen in the central nervous system (CNS) (36%) andbone (16%) compared to lung (89%), subcutaneous (83%),
spleen (71%), liver (85%) and lymph nodes/soft tissue (83%), P < 0.001. CNS was also the most common site of
progression.Based on this, we tested in vitro the efficacy of the BRAF inhibitors PLX4720 and dabrafenib in the
presence of cerebrospinal fluid (CSF). Exogenous CSF dramatically reduced cell death in response to both BRAF
inhibitors. Effective cell killing was restored by co-administration of a PI-3 kinase inhibitor.We conclude that the
efficacy of vemurafenib is variable in different organs with CNS being particularly prone to resistance. Extrinsic
factors, such as ERK- and PI3K-activating factors in CSF, may mediate BRAF inhibitor resistance in the CNS.
Introduction
The selective BRAF inhibitors vemurafenib and dabrafe-
nib are systemic treatments in patients with metastatic
melanoma harbouring a V600 BRAF mutation, which
accounts for roughly half cutaneous melanoma. BRAF
V600 mutations activate the ERK/MAPK pathway, which
plays an essential role in cell proliferation, differentiation
and survival. Treatment with BRAF inhibitors results in
high objective response rates, but progression occurs
after an average of 6–7 months (McArthur et al., 2014).
Although extensively studied over the last few years,
resistance mechanisms to BRAF-targeted kinase inhibi-
tors have not yet been fully understood (Bucheit and
Davies, 2014). Multiple primary and acquired resistance
mechanisms have been identified including those that
lead to reactivation of the MAPK pathway and MAPK-
independent pathways, such as the PI3K/AKT/mTOR/
cyclin D1/CDK4 retinoblastoma pathways (Bucheit and
Davies, 2014). Melanoma cell intrinsic resistance to BRAF
inhibitors seems to be diverse and independent resistance
mechanisms may even develop in parallel in different
tumour lesions (Chan et al., 2014; Menzies et al., 2014;
Wilmott et al., 2012). Conversely, if progression occurs in
one organ with ongoing response, in other organs,
melanoma cell extrinsic factors may play a crucial role.
Significance
Our clinical data show that the response to BRAF-targeted therapy is highly variable dependent on the
anatomical sites ofmetastaseswithCNSas aparticular resistant site.Weprovide scientific evidence that BRAF
inhibitor resistance in the CNSmay bemediated bymelanoma cell extrinsic factors in the cerebrospinal fluid.
This requires further identification of those specific and potentially targetable factors in the future.
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Patients with active metastatic central nervous system
(CNS) disease were excluded from the initial registration
trials of vemurafenib and dabrafenib and as a result, the
efficacy of BRAF inhibitors in the CNS was uncertain and
based on case reports. More recently, the results of
phase II trials in metastatic melanoma patients with brain
metastases demonstrated efficacy of both BRAF inhibi-
tors vemurafenib and dabrafenib in the brain; however,
progression-free survival was short-lived with approxi-
mately 4–6 months only (Azer et al., 2014; Dummer
et al., 2014; Kefford et al., SMR 2013; Long et al., 2012).
In patients with CNS metastases treated with dabrafenib,
extra- and intracranial PFS was similar and there was little
difference seen in efficacy between extra- and intracranial
sites, but number of patients was limited (n = 23) and the
analysis did not discriminate between sites of extracranial
metastasis or the possibility that there was a larger initial
number of extracranial metastases (Azer et al., 2014).
Case reports have also reported solitary brain progression
on vemurafenib with ongoing extracranial response, and
different resistance mechanisms in the brain have there-
fore been suggested (Papadatos-Pastos et al., 2013).
Here, we present organ-specific efficacy and resistance
data from a single-institution retrospective analysis of
BRAF V600-mutant metastatic melanoma patients with
progression on vemurafenib. We also provide experimen-
tal evidence that the poor responses of CNS metastases
to vemurafenib and dabrafenib can be due to extrinsic
factors present in cerebrospinal fluid (CSF).
Results
Clinical characteristics of the patient cohort
At time of evaluation, 68 patients treated with vemu-
rafenib as a single agent for metastatic melanoma at our
institution had stopped treatment due to radiologically
confirmed progressive disease. Their pattern of progres-
sion is presented here. Baseline characteristics are
summarized in Table 1. The majority of patients (69%)
were treatment na€ıve before starting vemurafenib. The
distribution of metastatic disease at baseline is presented
in Table 2. The most common metastatic site was lymph
nodes/soft tissue (81%). Metastatic CNS disease was
present in 21% at baseline with a CT/MRI brain scan
available in 81% of the patients. Thus, this group of
patients reflects the normal metastatic pattern for
melanoma.
Pattern of response and progression
Median time on vemurafenib until progression was
4.1 months (95% CI: 0.9–17.1). Overall, one patient
(1%) on vemurafenib showed complete remission (CR),
68% partial response (PR), 18% SD and 13% progressive
disease (PD) as best response. We assessed whether the
responses were equivalent at different metastatic loca-
tions. As shown in detail in Figure 1(A) and Table 2, CR or
PR was more common in metastatic disease in the lung
(89%), liver (85%), lymph nodes/soft tissue (83%),
subcutaneous (83%) and spleen (71%), whilst they were
less common in the CNS (36%) and bones (16%),
P < 0.01 by Fisher’s exact test. Primary refractory
disease was most common in bone and CNS disease
Table 1. Baseline characteristics (n = 68)
Age, years (range) 53 (18–77)
Male, n (%) 39 (57)
Stage M1c, n (%) 55 (81)
Elevated LDH, n (%) 48 (71)
ECOG PS ≥ 2, n (%) 11 (16)
Systemic treatment prior to vemurafenib, n (%) 21 (31)
Number of metastatic organ sites at baseline
1, n (%) 12 (18)
2, n (%) 11 (16)
≥3, n (%) 45 (66)
Table 2. Organ-specific pattern of response and progression
Baseline
Best response* Progression
CR/PR PD Overall Previous site New site Solitary site
n (% total) n (% BL) n (% BL) n (% total) n (% BL (+)) n (% BL ()) n (% total**)
Total, n (%) 68 47 (69) 9 (13) 68 (100) 65 (96) 20 (29) 20 (29)
LN/ST 55 (81) 45 (83) 5 (9) 35 (51) 35 (65) – 9 (14)
Lung 35 (51) 31 (89) – 16 (24) 14 (40) 2 (6) 2 (3)
Liver 33 (49) 28 (85) 3 (9) 19 (28) 18 (55) 1 (3) 2 (3)
Subcutaneous 29 (43) 24 (83) – 14 (21) 13 (45) 1 (3) –
Bone 19 (28) 3 (16) 3 (16) 13 (19) 8 (42) 4 (8) 2 (3)
CNS 14 (21) 5 (36) 2 (14) 19 (28) 11 (79) 6 (11) 4 (6)
Spleen 7 (10) 5 (71) – 6 (9) 4 (57) 2 (3) –
NOS 14 (21) 11 (79) 1 (7) 14 (21) 10 (71) 4 (7) 1 (2)
CR, complete remission; PR, partial response; PD, progressive disease; LN/ST, lymph nodes/soft tissue; CNS, central nervous system; NOS, not
otherwise specified.
*1 patient with CT head only to assess best response.
**3 patients with CT head only at PD; BL (+) known metastatic disease in specific organ at baseline; BL () no metastatic disease in specific organ
at baseline.
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(16 and 14%, respectively). Complete imaging (CNS/
thorax/abdomen/pelvis) at baseline and progression was
available in 24 patients and confirms poorer responses in
CNS and bone (Figure 1B).
At progression, in 65 of 68 patients, a CT thorax/
abdomen/pelvis was available for review, whilst in three
patients, only CT head was performed. This enabled us to
evaluate whether progression was equally common in
different organs. Progression in 1, 2 or ≥3 organ sites was
seen in 29, 43 and 24% of the 68 patients, respectively.
The most common site of progression on vemurafenib
was the CNS; 79% of the patients with previously known
CNS metastases progressed in the CNS. This contrasts
with 40, 45, 55, 57 and 65% progression of lung,
subcutaneous, liver, spleen and lymph node/soft tissue
metastases, respectively (Figure 1C). The same pattern
was even more evident when analysis is restricted to the
patients with complete imaging (CNS/thorax/abdomen/
pelvis) at baseline and progression (Figure 1D). Further,
the CNS was the most common site for new metastases
to arise (Figure 1E,F). Patients with progression within
the CNS showed a trend to poorer OS compared to those
A B
C D
E
G
F
Figure 1. Organ-specific response and progression pattern. (A) Organ-specific best response in %. Fisher’s exact test indicates that the disease
response is significantly worse in the CNS and bones compared to lung, subcutaneous, spleen, liver and lymph nodes/soft tissue (P < 0.01). n,
number of patients with organ-specific metastatic disease at baseline and available CT scans for assessment; CR, complete remission; PR, partial
remission; SD, stable disease; PD, progressive disease; subcut, subcutaneous; LN/ST, lymph nodes/soft tissue; CNS, central nervous system. (B)
Similar to (A) except restricted to patients with CNS, abdomen and thorax imaging at both presentation and progression. (C) Organ-specific
progression (PD) at previous metastatic site: (n) number of patients with known metastatic site at baseline (BL (+)). (D) Similar to (C) except
restricted to patients with CNS, abdomen and thorax imaging at both presentation and progression. (E) Organ-specific progression (PD) on new
sites: (n) number of patients with no previous metastatic site at baseline (BL ()). (F) Similar to (E) except restricted to patients with CNS,
abdomen and thorax imaging at both presentation and progression. (G) Imaging of a patient with multiple intraparenchymal brain metastases at
baseline (left side of right panel) with evidence of several liver metastases (left side of left panel). After 2 months of treatment with vemurafenib,
the patient showed clinical symptomatic progression in the CNS with several new brain metastases (right side of right panel), but response in the
liver (right side of left panel).
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without (median OS 6.0 months (95% CI: 2.1–9.9) versus
9.0 (95% CI: 7.5–10.5), P = 0.862).
Progression pattern in central nervous system
disease
With CNS being the most common site of progression,
we further assessed the pattern of response and
progression in the CNS in detail. Of 14 patients with
CNS disease at baseline, 11 patients had parenchymal
brain lesions, two patients had meningeal disease, and
one patient had both parenchymal and meningeal dis-
ease. One patient had received prior CyberKnife treat-
ment on two parenchymal lesions, one patient had
received whole-brain radiotherapy (WBRT) for one lesion,
and another patient had WBRT for multiple lesions. In
these 14 patients, PR, SD and PD were seen in 5 (36%), 7
(50%) and 2 (14%) patients, respectively (Table S1). In
four of the five patients with response to vemurafenib,
only a solitary brain metastasis was present at baseline,
while one patient presented with meningeal disease.
None of these patients had received brain radiotherapy
prior to vemurafenib. Amongst the patients with stable
CNS disease (parenchymal n = 5, meningeal n = 1, both
n = 1), only two patients showed more than one
parenchymal metastases and they received CyberKnife
or WBRT prior to vemurafenib. Ultimately, both of these
patients showed progression on the irradiated sites. Both
patients with primary refractory CNS disease presented
with multiple brain metastases at baseline, but had not
received WBRT before starting vemurafenib.
At cessation of vemurafenib, 19 of 68 patients (28%)
showed progression within the CNS with a CT thorax/
abdomen/pelvis available in 18 patients. Twelve of these
patients (66%) showed synchronous progression within
and outside the CNS. CNS progression only was seen in
four of the 18 patients (22%) including one patient with
meningeal disease. Images of a patient with intracranial
disease progression, but ongoing extracranial response,
are shown in Figure 1G. Progression outside the CNS
with ongoing response within the CNS was seen in two
patients with an asymptomatic solitary small volume brain
metastasis at baseline.
In vitro analysis of a potential extrinsic resistance
mechanism of BRAF inhibitors in the central nervous
system
Based on the analysis above, we hypothesized that there
may be some distinctive feature of the CNS environment
responsible for the poor responses to vemurafenib.
Cerebrospinal fluid contains various growth factors and
cytokines, some of which are reported to activate ERK/
MAP kinase signalling in a Ras-dependent manner (Bilic
et al., 2006; Lok et al., 2014). Thus, we decided to
explore the direct effect of CSF on the response to BRAF
inhibition. We established a BRAF-mutant melanoma cell
line expressing an ERK/MAP kinase ‘biosensor’ (Hirata
et al., 2015; Komatsu et al., 2011). The biosensor is an
engineered polypeptide that contains two fluorophores
and can be phosphorylated by ERK/MAP kinase. This
phosphorylation event leads to a conformational change
in the polypeptide that repositions the fluorophores and
alters the fluorescent properties of the molecule. The
change in fluorescence can be monitored by live cell
microscopy, thereby providing a dynamic read-out of ERK/
MAP kinase activity in BRAF-mutant melanoma cells.
The upper panel in Figure 2(A) shows the baseline
activity of ERK/MAP kinase in murine BRAF-mutant
melanoma cells (Dhomen et al., 2009). This is somewhat
heterogeneous but does not change during 12 h of live
cell imaging. In contrast, if the BRAF inhibitor PLX4720 is
added after 5 min of imaging, then there is a sharp
reduction in ERK/MAP kinase activity (this is visible as a
‘blue shift’ in the false colour scale in Figure 2A–C). The
reduction in ERK/MAP kinase activity persists for several
hours until the melanoma cells begin to die (movie 1 and
quantified in Figure 2).
We next investigated what happens if melanoma cells
are cultured in the presence of CSF isolated from rats. In
the presence of CSF but absence of PLX4720, the activity
of ERK/MAP kinase is similar to controls but marginally
increases during the 12-h imaging session. The addition
of PLX4720 causes a reduction in ERK activity after 5 min
in both control and CSF cultures. However, in the
presence of CSF, the reduction in ERK/MAP kinase
activity is short-lived, and after 12 h, is undistinguishable
from that prior to PLX4720 addition. This demonstrates
that exogenous CSF dramatically shortens the kinetics of
BRAF-mutant melanoma cell response to PLX4720. This
is correlated with a failure of the melanoma cells to die
(movie 1 and quantified in Figure 3A). We confirmed that
CSF provides protection against the effect of BRAF
inhibition using a second drug, dabrafenib (Figure 3A).
The apoptotic nature of PLX4720-induced cell death and
its reduction by exogenous CSF were confirmed by live
staining using cell viability markers. Both propidium iodide
and annexin V staining confirmed the ability of CSF to
counteract the effects of BRAF inhibition (Figure 3B,C
and Figure S1A). Further, the detection of annexin V-
positive cells that retained nuclear integrity confirmed the
early externalization of phosphatidylserine, which is a
hallmark of apoptotic cell death (yellow arrow in Fig-
ure S1A). We sought to validate our observations about
the protective effect of CSF in models of human V600-
mutant melanoma. Both A375 and WM266.4 human
melanoma cell lines harbour BRAF mutations and are
sensitive to PLX4720 (Figure 3D,E). The effect of
PLX4720 is reduced in both cell lines by adding exoge-
nous CSF. We additionally confirmed that CSF prevents
PLX4720 from reducing overall cell numbers (Figure S1A,
B). These data demonstrate that CSF reduces the efficacy
of BRAF inhibition in multiple models, including human
melanoma cells.
We next sought to understand which signalling
pathways might be mediating the protective effect of
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CSF. We hypothesized that either the re-activation of
ERK/MAP kinase signalling or PI-3 kinase signalling may
be important; the latter can be activated by factors in
CSF such as IGF-1 and IL-6 (Bilic et al., 2006; Protas
et al., 2011). To test the functional significance of these
pathways, we combined PLX4720 treatment with either
a MEK inhibitor, PD184352 or a pan PI-3 kinase
inhibitor, LY294002. Figure 4A shows that combined
blockade of BRAF and PI3K isoforms synergizes to
reduce melanoma cell number in the presence of CSF.
Interestingly, CSF provided significant protection
against the effect of either MEK inhibition alone or
combined BRAF and MEK inhibition. These data indicate
that the protective effects of CSF are largely mediated
via PI-3 kinase signalling.
Discussion
Our clinical data demonstrate that vemurafenib shows
efficacy in all organs and this concurs with the observa-
tion of others (Dummer et al., 2014; Kefford et al., SMR,
2013), but the efficacy appears highly variable depending
on anatomical sites. We found that lymph node/soft
tissue, lung, liver, spleen or subcutaneous metastases
respond better than either CNS or bone metastases.
Moreover, the CNS was also the most common site
where resistance emerged during treatment with vemu-
rafenib. The different responses seen in the bone and
CNS were highly significant. These patterns of response
hold true for both the analysis of all 68 patients and the 24
patients for whom complete imaging at both presentation
A
B
C
Figure 2. Cerebrospinal fluid (CSF)
counteracts the ability of PLX4720 to reduce
ERK/MAP kinase activity. (A) Time-lapse
images of 5555 mouse melanoma cells stably
expressing EKAREV-NLS biosensor cultured in
DMEM or DMEM containing 50% rat CSF,
treated with 0.1% DMSO or 1 lM PLX4720 (at
time 0, indicated by an arrowhead). Images
were acquired every 5 min for 13 h. See also
Movie S1. Scale bar = 100 lm. (B)
Kymographs showing ERK/MAPK biosensor
FRET activity of five representative cells either
treated with 1 lM PLX4720 in DMEM (upper
set) or 1 lM PLX4720 in 50% CSF (lower set).
Black crosses indicate cell death. (C)
Quantification of ERK/MAPK biosensor activity
of 5555 cells treated with PLX4720 in DMEM
(top) or DMEM + 50% CSF (bottom). Each dot
in the graphs represents ERK activity in a single
cell, normalized to before treatment.
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and progression was available. Although difficulties can
arise in the unambiguous assessment of disease in the
bone and CNS and only contrast CT scan without MRI
was available at baseline, these are highly unlikely to
account for the pattern of response that we observe. We
suggest, therefore, that the CNS and bones represent an
environment, where organ-specific extrinsic factors may
play an important role in BRAF inhibitor resistance. The
poor responses in the bone are consistent with our recent
findings that stiff microenvironments rich in matricellular
molecules enable BRAF-mutant melanoma to tolerate
BRAF inhibition (Hirata et al., 2015). Our findings are
consistent with a previous report that the outcome of
CNS disease is poor (Meier et al., 2004).
As demonstrated in the published results of the phase
II trials of single-agent vemurafenib or dabrafenib in
patients with untreated and treated brain metastases
(Dummer et al., 2014; Kefford et al., SMR, 2013; Long
et al., 2012), our data confirm efficacy of vemurafenib in
the CNS, but secondary resistance to vemurafenib was
almost universal. Only patients with low volume CNS
disease showed response in our study; all patients with
multiple brain metastases showed primary refractory
disease. Interestingly, 4 patients showed CNS progres-
sion only with ongoing response outside the CNS.
Without detailed analyses of biopsies from both respond-
ing and non-responding metastases in the same patient, it
remains unclear whether primary resistant CNS disease
or solitary CNS progression is due to melanoma cell
intrinsic mechanisms or extrinsic factors. Nonetheless,
the pattern of poor responses in the CNS across the
whole group of patients suggests that extrinsic factors
may play a role.
Preclinical data suggest limited efficacy of BRAF
inhibitors within the CNS due to active drug efflux
transporters such as P-glycoprotein (ABCB1) and breast
cancer resistance protein (BRCP or ABCG2) (Mittapalli
et al., 2013). Other explanations so far are the limited
penetration of the blood–brain barrier due to the chemical
characteristics of the BRAF inhibitor vemurafenib with
relatively large molecular weight and poor lipid solubility
(Wager et al., 2011). Inflammatory changes of the blood–
brain barrier, such as caused by WBRT, are known to
allow greater drug penetration. However, in the phase II
trial with the BRAF inhibitor dabrafenib and vemurafenib,
no difference between patients with metastatic brain
disease with or without prior local treatment (surgery or
radiotherapy) was seen in the outcome (Kefford et al.,
SMR, 2013; Long et al., 2012). Therefore, restricted
permeation of BRAF inhibitors into the CNS may not be
the most important limitation in efficacy.
In our in vitro tests, exposure of PLX4720-sensitive
melanoma cells to cerebrospinal fluid resulted in an
upregulation of ERK signalling. Thus, the presence of high
levels of ERK-activating factors in the CSF/CNS may
explain one potential extrinsic source for BRAF inhibitor
A
C D E
B
Figure 3. Cerebrospinal fluid (CSF)
counteracts the ability of BRAF inhibitors to
induce cell death. (A) Histogram shows the cell
death of 5555 cells cultured in DMEM or 50%
CSF treated with DMSO, 1 lM PLX4720 or
1 lM dabrafenib. ***P < 0.001. The
percentage of cell death observed in each
treatment group during a 12-h movie was
quantified (unpaired t-test, n = 4). (B) Images
show cell death of 5555 cells cultured in
DMEM or 50% CSF treated with DMSO or
1 lM PLX4720 or 1 lM dabrafenib. Propidium
iodide staining is shown in magenta, and
nuclear GFP staining is shown in green. Scale
bar is 100 lm. (C) Quantification of cell death
induced by 1 lM PLX4720 or 1 lM dabrafenib
in 5555 cells cultured in DMEM or 50% CSF
(n = 3). **P < 0.01, ***P < 0.001. (D)
Quantification of cell death induced by 1 lM
PLX4720 in A375 cells cultured in DMEM or
50% CSF (n = 3). **P < 0.01. (E)
Quantification of cell death induced by 1 lM
PLX4720 in WM266.4 cells cultured in DMEM
or 50% CSF (n = 3). **P < 0.01.
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resistance in the CNS. However, combined blockade of
BRAF and MEK was relatively ineffective in the presence
of CSF and cotargeting of BRAF PI-3 kinase was much
more effective. This implies a significant role for PI-3
kinase signalling triggered by CSF, which is consistent
with the work of Chen and colleagues (Chen et al., 2014).
Further, higher activation of the AKT survival pathway has
been demonstrated in astrocyte-conditioned medium
compared to fibroblast-conditioned medium and inhibition
of PI3K/AKT signalling resensitized melanoma cells iso-
lated from a vemurafenib-resistant brain metastasis
(Niessner et al., 2013). In the future, it will be interesting
to identify the specific factors within CSF that promote
ERK activity and determine whether they might be
therapeutically targeted. Indeed, high levels of IGF-1
have been reported in CSF and its receptor would
represent a ‘druggable’ target (Pyonteck et al., 2013).
Recent preclinical data showed potent activity of MEK/
ERK inhibitors (Carlino et al., 2014;). But limited brain
distribution was demonstrated in MEK inhibitors (Vaid-
hyanathan et al., 2014) and the clinical benefit of MEK
inhibitors in patients with CNS metastases is currently
investigated in an ongoing trial (COMBI-MB –
NCT02039947 (2015)). Our data argue that even com-
bined inhibition of BRAF and MEK may have limited
efficacy against brain metastases.
To conclude, our analysis of melanoma response to
vemurafenib depending on anatomical location reveals
that CNS disease is particularly problematic. We propose
that cell extrinsic factors in the CNS environment provide
a BRAF-independent mechanism for ERK/MAP kinase
activation. We demonstrate experimentally that CSF
greatly diminishes the responsiveness of BRAF-mutant
melanoma cells to PLX4720. In the future, it will be
interesting to perform more detailed analyses of biopsies
from different locations in the same patient to determine
the role of cell intrinsic versus extrinsic factors in the
varying response of disease at different sites. Greater
understanding of the mechanisms of organ-specific influ-
ences on metastases, and how to counteract them,
should lead to improvements in the utility of available
targeted therapies in metastatic melanoma.
Methods
Clinical and imaging review
Retrospectively, we analysed all patients that had been treated with
and progressed on vemurafenib as a single agent for metastatic
melanoma harbouring a BRAF V600 mutation at a single institution
(Royal Marsden Hospital, London, UK) from March 2010 to May
2013. Patients were treated within the BRIM-3 study
(NCT01006980), the vemurafenib safety study (NCT01307397) as
well as off trial after the European Medicines Agency (EMA) approval
of vemurafenib in December 2011. Exclusion criteria were as
follows: cessation of vemurafenib for reasons other than progressive
disease, for example toxicity, and lack of radiological confirmation of
progressive disease. Contrast CT/MRI scans at baseline, during
treatment and at progression were assessed for overall best
response per Response Evaluation Criteria in Solid Tumours (RECIST)
version 1.1. Organ-specific response was assessed using a modified
form of RECIST 1.1 criteria: any reduction in target lesions was
assessed as PR, stable appearance was defined as stable disease
(SD), and growth of ≥20% in one lesion or the sum of the organ
lesions or any new lesion was defined as primary refractory disease if
present on first evaluation scan or as PD on subsequent scans. The
regulatory oversight of this study was by the Royal Marsden Hospital/
Institute of Cancer Research Committee for Clinical Research.
In vitro analyses
Cells, probes and reagents
BRAF-mutant 5555 mouse melanoma cells are described in Manning
et al. (2013, 2015) and were a kind gift from Professor Richard
Marais (The CRUK Manchester Institute, UK). A375 and WM266.4
human melanoma cell lines were a gift from Professor Chris Marshall
(Institute of Cancer Research, London, UK). Melanoma cells were
maintained in DMEM supplemented with 10% FBS (Dhomen et al.,
2009). The prototype FRET biosensors for ERK/MAPK (EKAREV-NLS)
were described previously and are a kind gift from Professor
Michiyuki Matsuda (Kyoto University, Japan) (Komatsu et al., 2011).
A
B
Figure 4. BRAF and PI-3 kinase inhibitions synergize to reduce cell
viability in the presence of cerebrospinal fluid (CSF). (A) Histogram
shows the cell viability of 5555 luciferase cells cultured in DMEM or
50% CSF treated with DMSO, 1 lM PLX4720, 1 lM PD184352 or
10 lM LY294002. Cell viability was measured by assessing
luciferase activity (n = 4). *P < 0.05, **P < 0.01. (B) Model of BRAF
inhibition in the presence of CSF: scheme shows how CSF can
activate ERK/MAPK signalling in a BRAF-independent manner and PI-
3 kinase signalling. These events combine to reduce the efficacy of
BRAF inhibitors in the presence of cerebrospinal fluid.
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The probe was introduced into the cells with PiggyBac transposon
system (Wellcome Trust Sanger Institute, UK). PLX4720 was
obtained from Stratech (#S1152) and used at the final concentration
of 1 lM. The COSHH and genetic modification regulatory oversight
of this work was performed by the London Research Institute Health
and Safety Committee.
Collection of rat cerebrospinal fluid
Rat CSF was collected from male Wistar rats as described elsewhere
(Liu and Duff, 2008). Briefly, animals were euthanized by overdose
carbon dioxide and fixed on a surgical stage. After dissecting occipital
muscle layers, CSF (~150 ll/rat) was directly collected with a
microsyringe by punctuating Cisterna Magna. Collected CSF was
aliquoted and kept at -80⁰C until experimental use.
Time-lapse FRET imaging and image processing
5555-EKAREV-NLS were seeded onto a glass bottom 96-well plate
and cultured in 100 ll phenol red-free DMEM (GIBCO/Thermo Fisher
Scientific, Waltham, MA, USA) or mixture of 50 ll phenol red-free
DMEM and 50 ll rat CSF. For the dual-emission ratio imaging, we
used Zeiss 780 inverted microscope with 209 dry objective (Nikon
Instruments Europe B.V., Amsterdam, Netherlands). The FRET
biosensor was excited by a Chameleon Ti: Sapphire Laser (Coherent
Inc., Cambridgeshire, UK) at 820 nm excitation wavelength through
IR cut filter (MBC 760). The emission light was separated by beam
splitters into 463–506 nm for CFP and 515–559 nm for YFP/FRET.
Images were acquired as 12-bit images and analysed with METAMORPH
software (Universal Imaging), as described previously (Hirata et al.,
2012).
Cell viability assay
A total of 25 000 melanoma cells were seeded on 96-well glass
bottom plates, cultured overnight and then treated with DMSO
(0.4%), PLX4720 (1 lM), dabrafenib (1 lM), PD184352 (1 lM),
LY294002 (1 lM) or the combinations for 24 h. For cell death
analysis, melanoma cells stably expressing YFP in the nuclei were
stained with propidium iodide (PI) at the final concentration of 1 mg/
ml and imaged with Zeiss 780 inverted microscope. Then, PI-positive
areas were calculated per the number of surviving cells. For cell
proliferation assay, melanoma cells stably expressing firefly lucifer-
ase were seeded and treated in the same manner, and after adding
D-Luciferin (150 lg/ml), the plates were imaged under IVIS Spectrum
(Parkin Elmer).
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. (A) Images show cell death of 5555 cells
cultured in DMEM or 50% CSF treated with DMSO or
1 lM PLX4720 or 1 lM dabrafenib. Annexin V staining is
shown in magenta and nuclear GFP staining is shown in
green. White arrow highlights cell in the early stages of
apoptosis – nuclear morphology normal but annexin V
+ve, yellow arrow highlights cell in later stages of
apoptosis – abnormal nuclear morphology and annexin V
+ve, orange arrow highlights apoptotic cell debris –
histone H1 is no longer visible but annexin V staining
can still be seen associated with the cell membrane.
Scale bar is 100 lm. Histogram shows Quantification of
cell death induced by 1 lM PLX4720 or 1 lM dabrafenib
in 5555 cells cultured in DMEM or 50% CSF (n = 6 fields
of view from two experiments). ***P < 0.001. (B) His-
togram shows the cell viability of A375-luciferase cells
cultured in DMEM or 50% CSF treated with DMSO or
1 lM PLX4720. Cell viability was measured by assessing
luciferase activity (n = 3). **P < 0.01. (C) Histogram
shows the cell viability of WM266.4-luciferase cells
cultured in DMEM or 50% CSF treated with DMSO or
1 lM PLX4720. Cell viability was measured by assessing
luciferase activity (n = 3). **P < 0.01.
Movie S1. CSF provides an extrinsic factor that
reactivates ERK in PLX4720 treated melanoma cells.
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